Single-center experience of surgically resected gastrointestinal stromal tumors: A report of six cases, including a rare case involving the lower esophagus
- Authors:
- Bilal O. Al‑Jiffry
- Hisham M. Allam
- Mohammed Hatem
View Affiliations
Affiliations: Department of Surgery, Taif University, Taif 21944, Saudi Arabia, Department of Surgery, Al‑Hada Military Hospital, Taif 21944, Saudi Arabia
- Published online on: December 11, 2014 https://doi.org/10.3892/ol.2014.2792
-
Pages:
745-748
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Gastrointestinal stromal tumors (GISTs) are rare, but remain the most common GI mesenchymal neoplasms. In the present study, six cases of GIST are reported, and one of these cases, a patient with esophageal GIST, is reported in-depth. Certain recent developments in the clinical therapy of GISTs are also discussed. The records of all surgically‑resected GI stromal tumors treated at the Al‑Hada Military Hospital between January 2007 and December 2012 were reviewed. There were six cases of surgically resected GISTs during this time period, three males and three females, with a mean age of 69.3±16.4 years. The stomach was involved in 66.7% of cases, the small intestine in 16.7% and the esophagus, which is an extremely rare site, in 16.7% of cases. The most common symptom at presentation was abdominal pain, followed by GI bleeding. The mean tumor size was 8.7±6.3 cm. Surgery was indicated by the presence of the aforementioned symptoms or a tumor size >5 cm. All tumors were completely resected with histologically negative margins. The diagnoses were established by immunohistochemistry. Four patients were classified as possessing a high‑grade variant, and were administered with tyrosine kinase inhibitors (TKIs). Following a mean follow up of 31 months, no recurrence or mortality was detected. Complete surgical resection with tumor‑free margins is the standard treatment for GISTs, and TKIs should be used as adjuvant therapy if the risk of progressive disease is high.
View References
|
1
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corless CL and Heinrich MC: Molecular
pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol.
3:557–586. 2008. View Article : Google Scholar
|
|
3
|
Edge SB, Byrd DR, Compton CC, et al:
Gastrointestinal stromal tumor. AJCC Cancer Staging Manual. 7th
edition. Springer; New York, NY: pp. 175–180. 2010
|
|
4
|
Demetri GD: Gastrointestinal stromal
tumor. DeVita VT Jr, Lawrence TS and Rosenberg SA: Cancer:
Principles and Practice of Oncology. 9th edition. Lippincott
Williams & Wilkins; Philadelphia, PA: pp. 1060–1073. 2011
|
|
5
|
Gold JS, van der Zwan SM, Gönen M, et al:
Outcome of metastatic GIST in the era before tyrosine kinase
inhibitors. Ann Surg Oncol. 14:134–142. 2007. View Article : Google Scholar
|
|
6
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors - definition, clinical, histological,
immunohistochemical, and molecular genetic features and
differential diagnosis. Virchows Arch. 438:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kindblom LG, Remotti HE, Aldenborg F and
Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT):
gastrointestinal stromal tumors show phenotypic characteristics of
the interstitial cells of Cajal. Am J Pathol. 152:1259–1269.
1998.PubMed/NCBI
|
|
8
|
Joensuu H, Fletcher C, Dimitrijevic S, et
al: Management of malignant gastrointestinal stromal cell tumours.
Lancet Oncol. 3:655–664. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blackstein ME, Blay JY, Corless C, et al;
Canadian Advisory Committee on GIST. Gastrointestinal stromal
tumours: consensus statement on diagnosis and treatment. Can J
Gastroenterol. 20:157–163. 2006.PubMed/NCBI
|
|
10
|
DeMatteo RP, Lewis JJ, Leung D, et al: Two
hundred gastrointestinal stromal tumors: recurrence patterns and
prognostic factors for survival. Ann Surg. 231:51–58. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Judson I and Demetri G: Advances in the
treatment of gastrointestinal stromal tumours. Ann Oncol. 18(Suppl
10): x20–x24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Søreide K, Sandvik OM, Søreide JA, et al:
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of
imatinib naïve adult patients with gastrointestinal stromal tumours
(GISTs) of the stomach and small intestine: relation to
tumour-biological risk-profile and long-term outcome. Clin Transl
Oncol. 14:619–629. 2012. View Article : Google Scholar
|
|
13
|
Blum MG, Bilimoria KY, Wayne JD, et al:
Surgical considerations for the management and resection of
esophageal gastrointestinal stromal tumors. Ann Thorac Surg.
84:1717–1723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HJ, Park SI, Kim DK and Kim YH:
Surgical resection of esophageal gastrointestinal stromal tumors.
Ann Thorac Surg. 87:1569–1571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Casali PG, Jost L, Reichardt P, et al;
ESMO Guidelines Working Group. Gastrointestinal stromal tumors:
ESMO clinical recommendations for diagnosis, treatment and
follow-up. Ann Oncol. 19(Suppl 2): ii35–38. 2008.PubMed/NCBI
|
